01/06/2026
A major breakthrough in pancreatic cancer research could signal the beginning of a new era of treatment.
Researchers in the United States have reported promising results from a Phase 3 trial of daraxonrasib, one of a new generation of drugs designed to target KRAS, a gene mutation found in more than 90% of pancreatic tumours.
The results suggest the treatment could effectively double life expectancy for some patients with advanced pancreatic cancer.
Importantly, this treatment is not currently available in the UK and has not yet been approved for use by UK regulators. However, the findings provide hope that KRAS inhibitors could become an important new treatment option in the future.
KRAS plays a key role in driving tumour growth and, for decades, scientists believed it was impossible to target with medicines. It was often described as "undruggable".
These latest results suggest that may finally be changing.
Daraxonrasib is just one of several KRAS-targeting drugs now being tested around the world. Together, these studies represent some of the most exciting developments in pancreatic cancer research for many years.
At Pancreatic Cancer Action, we welcome this progress while recognising there is still much work to do. We will continue to monitor developments closely and advocate for the investment, testing infrastructure and access needed to ensure patients can benefit from future advances.
Read our full statement: https://bit.ly/4dIAADj
To support our work, visit: https://bit.ly/43EtSrR
The latest results of a Phase 3 trial carried out by researchers in the US showed that daraxonrasib significantly improved overall survival in patients with advanced pancreatic cancer whose disease had progressed following previous treatment.